The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

Kisunla™ (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Saturday at the Dream Center, the Bismarck Memory Cafe hosted a presentation from the Alzheimer’s Association about recent ...

Eli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...

Kisunla is a newer treatment that works to slow down how fast Alzheimer’s progresses. It contains an antibody called donanemab-azbt, which targets and clears amyloid from the brain.

Kisunla is a prescription drug used to treat Alzheimer's disease. Find out whether it interacts with other drugs, alcohol, supplements, and more.

Microcap Cognition Therapeutics (NASDAQ:CGTX) has skyrocketed 35% in Thursday trading after stating the company had a ...